Survodutide 10 mg

Dragon Pharma Survodutide

Survodutide 10 mg represents the next generation of metabolic optimization peptides, combining dual agonism at both glucagon-like peptide-1 (GLP-1) and glucagon (GCGR) receptors for unprecedented fat loss and body recomposition results. Developed as BI 456906 in clinical research, Survodutide's innovative mechanism addresses two critical pathways simultaneously: GLP-1 receptor activation for appetite suppression, gastric emptying delay, and insulin sensitivity improvement, coupled with glucagon receptor stimulation for enhanced energy expenditure, lipolysis, and metabolic rate elevation.

Each vial contains 10 mg of pharmaceutical-grade Survodutide in lyophilized form, offering bodybuilders and physique athletes a powerful tool for contest preparation, cutting phases, and metabolic enhancement. Unlike single-action GLP-1 agonists, Survodutide's dual pharmacology creates a synergistic effect where reduced caloric intake (via GLP-1) combines with increased caloric burn (via glucagon), resulting in accelerated fat loss while potentially preserving lean muscle mass—a critical advantage during aggressive cuts where catabolism threatens hard-earned muscle.

The performance applications for strength athletes are transformative: dramatic reduction in subcutaneous and visceral adipose tissue, superior appetite control during calorie-restricted diets, improved insulin sensitivity for nutrient partitioning, potential muscle preservation through optimized amino acid utilization, and enhanced metabolic flexibility allowing more aggressive deficit phases. Additionally, Survodutide may support cardiovascular health markers and provide sustained energy levels despite significant caloric restriction.

Dragon Pharma's Survodutide undergoes rigorous quality control in EU-certified GMP facilities, ensuring >99% purity, accurate dosage, and absence of impurities. Independent third-party laboratory testing confirms each batch's potency—our September 2024 analysis verified 9.68 mg per vial, demonstrating Dragon Pharma's commitment to transparency and quality. The lyophilized formulation guarantees extended stability and maintains peptide integrity until reconstitution.

Key Benefits:

• Dual-Action Fat Loss: Combines appetite suppression (GLP-1) with increased metabolism (glucagon) for accelerated results.
• Superior Appetite Control: Powerful reduction in hunger signals and cravings during cutting phases.
• Metabolic Rate Enhancement: Glucagon receptor agonism increases energy expenditure beyond diet alone.
• Muscle Preservation Potential: May reduce catabolism during aggressive deficits through optimized nutrient partitioning.
• Improved Insulin Sensitivity: Enhances glucose disposal and nutrient utilization for better physique outcomes.

Each vial contains 10 mg of high-purity Survodutide peptide, manufactured under strict quality control standards in Dragon Pharma's certified facilities. Reconstitute with bacteriostatic water for subcutaneous administration tailored to your metabolic optimization goals.

Product Specifications

Usage Guidelines

Reconstitution: Add 2 mL of bacteriostatic water to the 10 mg vial, yielding 5 mg/mL concentration. Gently swirl until completely dissolved—avoid shaking. For precise low-dose titration, additional diluent may be added. Use within 30 days after reconstitution when refrigerated.

Administration: Subcutaneous injection in abdominal, thigh, or tricep adipose tissue. Rotate injection sites weekly to prevent lipohypertrophy. Best administered on a consistent schedule (e.g., every 3-4 days or weekly). Due to long half-life, consistent blood levels are maintained with less frequent dosing.

• Beginner Cycle (Weeks 1-4): 0.5-1 mg weekly, single dose. Assess gastrointestinal tolerance and appetite suppression. Ideal alongside T3 for metabolic synergy or L-Carnitine 500 for fat transport support.
• Intermediate Cycle (Weeks 5-12): 1.5-2 mg weekly, split into 2 doses. For active cutting phases. Stack with Anavar 10 for muscle preservation or Clenbuterol for thermogenic enhancement.
• Advanced Cycle (Weeks 13-16+): 2-3 mg weekly, split doses. For contest prep or aggressive recomposition. Combine with Masteron 100 for hardness or Winstrol 10 for cutting synergy.

Post Cycle Therapy (PCT):

Survodutide does not suppress HPTA, but appetite rebound should be managed. Taper down over 2-4 weeks rather than stopping abruptly. During transition, consider GW501516 to maintain metabolic rate. Monitor weight stabilization and adjust nutrition accordingly.

Liver & Pancreatic Health:

While generally safe, those with pancreatic or hepatic concerns should monitor closely. Consider liver support during extended use. Stay hydrated and ensure adequate protein intake to prevent excessive lean mass loss during aggressive deficits.

Third-Party Lab Tested

2024-09-13

View Result

9.68 mg

Note: Independent ISO-certified laboratory analysis confirms Dragon Pharma Survodutide potency and purity. September 2024 testing showed 9.68 mg per vial (96.8% of labeled 10 mg strength), within acceptable pharmaceutical variance. Additional testing confirms sterility and absence of bacterial endotoxins.

Storage Instructions

• Unreconstituted (Lyophilized Powder): Store at 2-8°C (36-46°F) in refrigerator. Protect from light exposure. Shelf life: 24 months from manufacture date. For long-term storage beyond 6 months, consider -20°C freezer in sealed container.
• After Reconstitution: Refrigerate immediately at 2-8°C (36-46°F). Use within 30 days. Do not freeze reconstituted solution. If solution becomes cloudy, discolored, or contains particles, discard immediately. Travel with insulated medical cooler.
• Handling Best Practices: Maintain strict aseptic technique. Use alcohol swabs on vial stopper and injection site. Never share needles or syringes. Dispose of sharps in proper containers. Wash hands before handling.